drugset / Trial / NCT00648765

Fed Study of Anagrelide Hydrochloride Capsules 1 mg to Agrylin® Capsules 1 mg

NCT00648765

Phase 1 Completed 22 enrolled Mylan Pharmaceuticals Inc
RandomizedCrossoverOpen-labelOther

Summary

The objective of this study was to investigate the bioequivalence of Mylan's anagrelide HCl 1 mg capsules to Shire US's Agrylin® 1 mg capsules following a single, oral 1 mg (1 x 1 mg) dose administration under fed conditions.

Timeline

Start
2003-01
Primary completion
2003-01
Completion
2003-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Anagrelide Small molecule 1 mg Oral

Indications

No indication recorded.